Arcus Biosciences (RCUS) Tops Q2 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($1.04), $0.06 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $29 million versus the consensus estimate of $31.81 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period